Author | Robert H. I. Andtbacka, MD | OncLive

Author | Robert H. I. Andtbacka, MD

Articles

Dr. Andtbacka on Optimal Use of T-VEC in Melanoma

June 27, 2016

Video

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.

Dr. Andtbacka on Ongoing Trials With Oncolytic Immunotherapies in Melanoma

February 09, 2016

Video

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as a treatment for melanoma.

Dr. Andtbacka on T-VEC Plus Ipilimumab in Unresected Melanoma

September 08, 2014

Video

Robert H. I. Andtbacka, MD, CM, from Intermountain Healthcare and Huntsman Cancer Institute, discusses the safety and efficacy of T-VEC in combination with ipilimumab in patients with previously untreated, unresected stage IIIB-IV melanoma.

Dr. Andtbacka Discusses OS With T-VEC in Melanoma

June 02, 2014

Video

Robert H. I. Andtbacka, MD, CM, from the Huntsman Cancer Institute, discusses OS findings from the phase III OPTiM study that explored T-VEC in patients with unresectable melanoma.

x